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Abstract
Background: Scleromalacia, in the form of scleral thinning, melting, and necrosis, is a potentially serious
complication of pterygium excision. This study introduces a new biodegradable material, Ologen™ collagen matrix
(OCM), to repair scleral thinning as an alternative to preserved scleral tissue, and evaluates the long-term outcomes
of OCM for ocular surface reconstruction surgery.
Case presentation: Two cases of possibly mitomycin C (MMC)-associated marked scleral thinning after pterygium
excision with 0.02 % topical MMC for 2-weeks were included in this study. An OCM graft at the scleral thinning area
and conjunctival autograft (CAU) were performed on both patients. The scleral defect size was measured and its
margin was marked with a biopsy punch. The margin of the scleral thinning area was trimmed by Vannas scissors
and the OCM was cut using a circular-shape biopsy punch of the same size. The OCM was sutured with a recipient
scleral wall using 10–0 nylon interrupted sutures. Free CAU was harvested from the superonasal bulbar conjunctiva
with a punch biopsy 1-mm larger in diameter than that of the OCM. The previously sutured OCM bed was covered
with CAU and the graft was secured with 10–0 nylon interrupted sutures. Both patients were examined periodically
for over two years by assessing graft thickness and surface vascularization using a slit lamp biomicroscope.
Reepithelialization of the ocular surface was observed within three to six days after surgery. Ocular discomfort and
inflammation ceased in both patients as the ocular surface quickly stabilized. The entire graft site remained intact
and provided a good healthy ocular surface with fluorescein stain negative intact epithelium and good
vascularization of grafted conjunctiva. Epithelial defects and scleral thinning did not recur in either patient over the
two year follow-up period.
Conclusion: For treatment of a possibly MMC-associated scleral necrosis following the surgical excision of the
pterygium, an OCM graft with CAU is highly recommended for good clinical outcomes and low recurrence rates.
With the clinical results of this study, the new biodegradable Ologen™ collagen matrix qualifies as an alternative
treatment to scleral tissue for ocular surface reconstruction.
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Background
Scleromalacia in the form of scleral thinning, melting, and
necrosis is a potentially serious complication of pterygium
excision. Scleromalacia has been observed after bare sclera
excision alone and may occur years or even decades after
the original surgery. The risk of scleromalacia seems to be
exacerbated by adjunctive therapies such as β-irradiation,
thiotepa, and mitomycin C (MMC) [1, 2]. Scleral necrosis
occurs in 0.2 to 4.5 % of patients, and higher risk is linked
to adjunctive use of MMC, especially more concentrated
or repeated doses [3].
If scleral thinning is severe and progressive, it can cause
visual loss from secondary infection and compromised
tectonic disintegrity of the globe by protrusion of choroidal
tissue even with minor trauma. Once an infection develops,
it is extremely difficult to control and may lead to the most
devastating complication, infectious scleritis. Therefore,
prevention of the catastrophic infection is more important
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than treatment, and the ocular surface reconstructive sur-
gery is required for therapeutic or tectonic reasons. The
technique of scleral patching with conjunctiva involves
mobilization of a flap of conjunctiva, with or without
attached Tenon’s fascia, and suturing of the flap over the
scleral defect. Other techniques include use of tarsocon-
junctival flap with autologous or homologous sclera, fascia
lata, tibial periosteum, split-thickness dermis, amniotic
membrane, aorta, dura, pericardium, or synthetic mate-
rials for patch graft [4–6].
In this study, we used the biodegradable material,
Ologen™ collagen matrix (OCM, Aeon Astron Europe
B.V., Leiden, The Netherlands), implant as graft tissue [7].
OCM as an implant does not require donor preserved
scleral tissue, the OCM is able to fill the space between
the CAU and scleral bed easily, and it helps the ocular
surface stay flat and regular. In this case study, we present
results of two years of observation for clinical outcomes
and complications of the OCM graft with CAU, and dem-
onstrate its clinical usefulness.
Case presentation
Case 1
A 70-year-old woman was referred to our institution in
July 2012 for treatment of left ocular pain. She complained
of ocular discomfort and decreased visual acuity (12/20) at
the first visit. She underwent nasal pterygium excision with
topical MMC in the left eye six years previously at another
facility. A few years after surgery, symptoms of intermit-
tent ocular discomfort and mild ocular pain developed, so
she went for treatment to a local medical center. She had
neither medical history or family history of ophthalmic
disease.
On slit-lamp examination, the underlying sclera at the
site of the prior pterygium excision was necrotic and avas-
cular, and showed marked thinning in the nasal portion of
the left eye (Fig. 1a). The scleral bed appeared conjunctivali-
zation over the exposed ciliary body with no evidence of
scleral perforation sign by Seidel test. The adjacent corneal
epithelium was intact and there was no anterior chamber
inflammatory reaction. We thought that the scleral thinning
was a possible MMC-associated thinning. Microbial smears
and cultures of the scleral bed were obtained at the first
visit, but were negative.
The patient was started on topical 0.1 % fluorometholone
and 0.5 % levofloxacin eye drops. Two weeks later, the
patient’s ocular pain and discomfort was gone. After
informed consent, the patient underwent an OCM graft
with CAU at the scleral thinning area. The surgical tech-
nique is described in Fig. 2. Proparacaine hydrochloride
eye drop (0.5 %, Alcaine; Alcon, Fort Worth, TX) was used
as topical anesthesia before surgery. First, the necrotic soft
tissues and devitalized sclera were surgically debrided with
a diamond burr, taking care not to damage the exposed
ciliary body and the unaffected adjacent conjunctiva.
Gentle polishing with a diamond burr instead of a knife
can produce a flat, regular surface without damaging the
already much thinned scleral bed. All necrotic scleral
tissue was dissected away until the scleral surface was
clean, smooth, and even. Conjunctival hemorrhage during
debridement was controlled by ocular bovie and cotton
swab compression. To determine the boundary for the
conjunctivectomy, the size of the scleral defect was mea-
sured and its margin was marked with a 3-mm diameter
biopsy punch (Fig. 2a, b). The margin of scleral thinning
area was trimmed by Vannas scissors and the OCM was
cut with a circular-shaped biopsy punch of the same size
(3-mm diameter). The OCM was trimmed and fitted to
cover the scleral defect (Fig. 2c). The OCM was sutured
with a recipient scleral wall using six stitches of 10–0
nylon interrupted sutures. The color of the OCM changed
from white to red due to blood accumulation (Fig. 2d).
Once the scleral defect was repaired, a 4-mm diameter,
circular, free CAU was harvested from the superonasal
bulbar conjunctiva with a punch biopsy 1 mm larger in
diameter than that of the piece of OCM. A conjunctival
graft that is larger than the scleral defect can achieve a
stable, tension-free graft to avoid a wound dehiscence
(Fig. 2e, f ). The CAU was carefully positioned over the
previously sutured OCM bed and anchored to the scleral
wall and the healthy conjunctival margin through the
OCM bed with 11 stitches of interrupted sutures of 10–0
nylon (Fig. 2g, h).
After surgery, the patient was given a patch dressing
with a topical antibiotic ointment (Erythromycin, Ecolicin®,
Taejoon Pharm., Seoul, Korea) and a steroid ointment
(Dexamethasone, Maxitrol®, Alcon Laboratories Inc., Fort
Worth, TX, USA) to be taken four times daily. The patient
was examined daily for the first five postoperative days.
After five days, the ointment patch dressing was replaced
by topical antibiotics (0.5 % levofloxacin, Cravit®, Taejoon
Pharm, Seoul, Korea) and steroid eye drops (0.1 % fluoro-
metholone, Flarex®, Alcon Laboratories Inc., Fort Worth,
TX, USA) to be taken four times a day. Inflammation of
the scleral bed subsided and the patient was comfortable.
The ocular surface was re-epithelialized six days after sur-
gery. The conjunctival sutures were removed at intervals of
one week to one month over the postoperative course.
Starting about one month after surgery, the topical 0.1 %
fluorometholone and 0.5 % levofloxacin eye drops were
tapered off over three months. Artificial tear substitutes
were used continuously after surgery. The patient was
examined weekly for the first two months and at three, four,
six, nine, 12, 16, 20, and 24 months postoperative.
Over the first postoperative month, the graft site vas-
cularized and was taken up well (Fig. 1c). The conjunc-
tival surface was stable at six months and 12 months
postoperative. When reviewed 24 months later, the
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conjunctival surface was still stable with no recurrence
of scleral thinning and scleromalacia (Fig. 1d).
Case 2
A 76-year-old man visited our institution complaining of
long standing ocular discomfort and decreased visual
acuity (16/20). He underwent nasal pterygium excision
with topical MMC in his left eye 10 years prior at another
facility. He had neither medical history or family history of
ophthalmic disease.
On slit-lamp examination, a focal epithelial defect at the
site of the prior pterygium excision and an approximately
3 mm scleral excavation with impending uveal exposure
were observed (Fig. 3a). At presentation, there was no sign
Fig. 1 Preoperative and postoperative slit-lamp photographs of Case 1, the left eye. a Preoperative photography showing large severe scleral thinning
and excavation with impending uveal exposure. b First week after surgery. c One month after surgery. d Two years after surgery
Fig. 2 The surgical procedure for Ologen™ collagen matrix (OCM) graft and conjunctival autograft surgery. a,b The size of the scleral defect was
measured and its margin was marked with a 3-mm diameter biopsy punch to determine the boundary of conjunctivectomy, c The margin of scleral
thinning area was trimmed by Vannas scissors and the OCM was cut with a circular-shaped biopsy punch of the same size (3-mm diameter). The OCM
was trimmed and fitted to cover the scleral defect. d The OCM was sutured with a recipient scleral wall using six stitches of 10–0 nylon interrupted
sutures. The color of the OCM changed from white to red due to blood accumulation. e A 4-mm diameter, circular, free CAU was harvested from the
superonasal bulbar conjunctiva with a punch biopsy 1 mm larger in diameter than that of the piece of OCM. f The CAU was carefully positioned over
the previously sutured OCM bed. g The CAU was anchored to the scleral wall and the healthy conjunctival margin through the OCM bed with 11
stitches of interrupted sutures of the 10–0 nylon. h Immediate final postoperative appearance
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of infectious scleromalacia. We thought that the scleral ex-
cavation was possibly an MMC-associated lesion. Microbial
staining and cultures were negative.
In the same manner as described in Case 1, steroid
and antibiotic eye drops were used before surgery. We
performed an OCM graft with CAU. Postoperatively, the
patient was treated with topical eye drops and examined
daily for the first postoperative week. Three days after
surgery, the OCM graft vascularized and was taken up
well. The surrounding conjunctival and scleral inflamma-
tion subsided and the patient was comfortable. The recon-
structed ocular surface was stable with no complications
during the two-year follow-up period (Fig. 3b,c,d).
Conclusions
A recently developed biodegradable porous collagen-
glycosaminoglycan (GAG) copolymer matrix implant is
proposed for glaucoma surgery because of its modula-
tory effect on wound healing [8–10].
The biodegradable collagen matrix implant marketed
as Ologen™ is a novel bioengineered implant designed to
be used during trabeculectomy [11]. The Ologen™ is an
upgraded biodegradable, implantable scaffold collagen
matrix consisting of lyophilized porcine atelocollagen
(>90 %) and lyophilized porcine glycosaminoglycan
(<10 %) with pore sizes of 10 to 300 μm. Atelocollagen
is a highly purified pepsin-treated type I collagen. A colla-
gen molecule has an amino acid sequence, a telopeptide,
at both the N and C terminals, which confers most of the
collagen’s antigenicity. Atelocollagen obtained by pepsin
treatment is low in immunogenicity, because it is free of
telopeptides [12].
Ologen™ is available in various shapes and dimensions.
When Ologen™ is placed into the subconjunctival space,
the porous structure guides conjunctival fibroblasts and
myoblasts to proliferate randomly and secrete connective
tissue in the form of a loose matrix during the wound
healing process. Therefore, it reduces scar formation and
wound contraction. Due to this mechanism, Ologen™ is
being used to enhance wound healing in ocular surface
reconstruction with low immunogenicity [9]. After Ologen™
implantation, the device completely degrades within 90–
180 days. The implant leaves behind a loose alignment of
collagen fibers inside scleral defects that is remarkably simi-
lar to normal tissue, with less scar formation than would
otherwise have occurred [9]. These findings suggest that
Ologen™ provides a physiological structure for tissue repair,
inducing a conjunctival wound to heal more in a physio-
logical than a pathological process. Therefore, this interven-
tional case series study, using Ologen™ as graft tissue for
scleral thinning and evaluating its long term outcomes, is
significant.
Other patching materials including preserved sclera,
amniotic membrane, and autologous fascia lata in
scleral patching are good donor material but still have
some limitations. For example, preserved homologous
sclera is a flexible avascular tissue that causes minor
immunologic reactions, infectious disease transmission,
and potential barrier to fibrovascular ingrowth. Corneal tis-
sue has a higher radius of curvature compared with sclera,
and placement of a large corneal patch on the scleral bed
usually results in a more raised lesion. Pericardium, fascia
lata, and dura are hard to obtain and sometimes require
additional surgery. Amniotic membrane is not suitable as
Fig. 3 Preoperative and postoperative slit-lamp photographs of Case 2, the left eye. a Preoperative photography showing irregular scleral thinning
and excavation with impending uveal exposure. b First week after surgery. c One month after surgery. d Two years after surgery
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space filling material [3]. Autologous scleral tissue grafts or
partial thickness scleral flap rotational procedures can be
used to patch scleral defects, although these procedures
potentially can damage the scleral tissue harvesting site,
especially in elderly patients like in this study. Therefore
the authors decided to try the new biomaterial instead of
autologous scleral tissue to avoid additional scleral or
ocular surface damage from the surgical procedure itself.
The Ologen™ material is mainly used in glaucoma filtering
surgeries because its porous and spongy structure permits
percolation of aqueous material during wound healing. The
authors believe that the Ologen™ material cannot provide
sufficient integrity, such as a tough-walled tunica sclerosa,
if there is large scleral thinning with an underlying uveal
protruding ectatic surface change. However, in the case of
a small scleral excavation without any underlying uveal
ectatic change, the porous, spongy properties of Ologen™
provide enough space filler effect for the duration of the
healing process of the wound with connective tissue
replacement.
In this study, we used the new biodegradable and
implantable material, Ologen™ as graft tissues for scleral
necrosis treatment after pterygium excision. In our
cases, all of the Ologen™ graft with CAU remained intact
and provided good healthy ocular surface; moreover,
recurrence of epithelial defect and scleral thinning was
not observed in either patient for over the two-year
follow-up period.
Our study shows the Ologen™ collagen matrix to be a
recommendable alternative material in ocular surface
reconstruction surgery for repair of scleromalacia. Based
on our results, the Ologen™ implant can induce host
tissue-collagen matrix interaction, optimize and stabilize
the structure, and prevent scar formation or further infec-
tion. Compared to scleral or other tissue graft, the Ologen™
graft is a time-saving, straightforward technique. As the
Ologen™ material is readily affordable, the Ologen™
graft is a valuable technique for cases in which donor
scleral tissue is unavailable or not accepted. Further-
more, we placed a conjunctival autograft over the OCM
implant to produce complete epithelialization of the
bare OCM surface while mitigating ocular surface
inflammation and patient discomfort for the duration
of the conjunctival epithelial migration. We expected
the meticulous conjunctival autograft overlying the
OCM implant to promote prompt epithelialization,
vascularization, and wound remodeling of the conjunc-
tival tissue.
There are some limitations to this study. First, quantita-
tive measurements of postoperative scleral thickness and
the integrity of the graft site using AS-OCT is needed in
more cases. Second, we believe the OCM graft applied in
this study is appropriate only for patients with a small
scleral excavation and no underlying uveal ectactic change.
Third, a larger number of participants will be required
to assess the clinical usefulness of the OCM implant
substitute for preserved sclera in scleral necrosis repair
surgery. Despite these limitations, this study provides a
new surgical technique with the application of new
materials to scleral necrosis surgery. The two-year
follow-up period was sufficient to evaluate the outcome
of the surgery. Ologen™ is commercially available sterile
material that surgeons can use to provide prompt
surface reconstruction. These are the main strengths of
this study. Ologen™ is currently used mainly in filtration
surgery of glaucoma. There are a number of possible
applications of OCM implants to ocular surface recon-
struction such as scleral thinning, recurrent pterygium,
and traumatic tissue defects. The patients’ perspective
of OCM graft in this study was that both felt comfort-
able after reepithelialization, without ocular discomfort,
ocular pain or severe foreign body sensation. Both were
satisfied with their ocular surface cosmesis over the two
years of observation.
In conclusion, our results suggest that the Ologen™ graft
with CAU is potentially a new, safe, easy, and effective
alternative treatment for ocular surface reconstruction,
especially in scleromalacia or scleral necrosis after surgical
excision of pterygium.
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